Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value

The 150-year-old drugmaker is the first company in health care to hit the milestone.

News
RFK Jr. Walks a Tightrope on Trump Deal for Obesity Drugs

The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling divisions between his supporters and the president.

News
Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy.

News
What Trump’s New Drug Pricing Deal Means for People With Obesity

The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

News
Trump Announces Deal to Drop Obesity Drug Prices to as Little as $150 a Month

President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.

News
Cardiovascular Benefits of Wegovy Extend Beyond Weight Loss, Study Shows

An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in people who took Wegovy.

News
Costco to Sell Ozempic and Wegovy, Weight-Loss Wonder Drugs

Costco members will pay $499 a month out of pocket, the same price offered at CVS and Walmart, and on the manufacturer’s direct-to-consumer website.

News
How Private Equity Oversees the Ethics of Drug Research

Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.

News
Targeting Hims & Hers, F.D.A. Takes on a New Type of Drug Advertiser

Regulators sent about 100 warning letters this week to drug advertisers, including to Hims & Hers, a major online provider of weight-loss drugs.

News
Trump Moves to Crack Down on Drug Advertising

The administration is proposing a return to a 1990s-era policy that kept most drug ads off TV. That could dent the revenues of drugmakers and major networks.

News